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Objectives: The epidemiological patterns of endemic hepatitis A virus (HAV) are
unclear in northeastern Asia depending on the ethnicity of the country in ques-
tion. The purpose of this study was to investigate the seroprevalence of HAV in
northeastern China, South Korea, and Japan.
Methods: A total of 1,500 serum samples were collected from five groups of
inhabitants (300 each) who were over 40 years of age (Korean Chinese, indige-
nous Chinese, South Korean, Korean living in Japan, and indigenous Japanese).
The samples were screened for antibodies to HAV using an enzyme-linked
immunosorbent assay.
Results: Positivity for HAV antibodies was 93.7% (95% confidence interval [CI]:
90.9e96.4) in Koreans living in northeastern China, 99.7% (95% CI: 99.0e100.3) in
indigenous Chinese, 98.0% (95% CI: 96.4e99.6) in indigenous Koreans, 33.3% (95%
CI: 28.0e38.7) in Koreans living in Japan, and 20.4% (95% CI: 15.8e25.0) in
indigenous Japanese persons. The overall anti-HAV prevalence was not signifi-
cantly different between northeastern China and South Korea, but it was
different in Japan.
Conclusions: These results indicate that differences in seroprevalence can be
attributed to geological, environmental, and socioeconomic conditions rather
than ethnicity., confidence interval.
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Hepatitis A virus (HAV) is transmitted via the oral-
fecal route, mainly by the consumption of contaminated
water, and is found worldwide. The epidemiologic
patterns (e.g., low, intermediate, and high) of ende-
micity are dependent on age and the level of hygiene
[1e3]. Even within a designated country, each pattern
is reflective of the variable infection rate, prevailing age
of the population, and mode of transmission [4,5].
Although the seroprevalence of HAV is low in children
in industrialized countries with low levels of ende-
micity, the age group of the most susceptible population
will change from children to older children and adults in
these countries [6e8]. Recently, severe cases of HAV
infection in nonimmune and nonimmunized adults have
been on the rise [2,8,9].
In developing countries, low economic status, high
population density, and inadequate water treatment
might contribute to higher levels of endemicity; more
than 90% of the population acquires natural immunity
before 10 years of age [5,10]. Due to improved stan-
dards of hygiene, sanitation, and socioeconomic condi-
tions, the epidemiological pattern of HAV infection
and other infectious diseases are currently undergoing
changes in many developing countries [4,10,11]. Studies
conducted in emerging countries have reported epide-
miological changes over the last several decades, indi-
cating that HAV affects the population at a later age
with an increased risk of manifesting in its symptomatic,
potentially more severe form [8,9,12].
This study was conducted in order to improve our
understanding of the comparative epidemiology of HAV
in northeastern China, South Korea, and Japan.2. Materials and Methods
2.1. Study design and population
This study is part of the Korean Emigrant Study
supported by the Korea Centers for Disease Control and
Prevention (KCDC). This study was initiated to eluci-
date the effects of environmental change, genetic
susceptibility, and their interaction of hypertension,
diabetes, and metabolic syndrome by comparing Korean
emigrants, their host country residents, and Koreans
living in Korea. The ratio between the two ethnic groups
was 1:1. From May 2005 to February 2008, a total of
3,142 men and women aged 40 years or over partici-
pated in the Korean Emigrant Study.
For this study, we randomly selected 300 Korean
emigrants, 300 Chinese in Yanbian, 300 Korean
emigrants, and 300 Japanese from the Kinki area
(western Japan). We also randomly selected 300
Koreans living in Korea who were matched in terms of
age and sex to the Chinese and Japanese sample
populations.2.2. Serologic tests and statistical analysis
To determine the seroprevalence in our study pop-
ulations, the presence of anti-HAV immunoglobulin
(IgG) in human sera was determined using Axsym
Abbott assays according to the manufacturer’s
instructions (Abbott Diagnostics Division, Wiesbaden,
Germany). We calculated the proportion of the HAV
antibody-positive persons and achieved a 95% confi-
dence interval (CI) using a modification of the Wald
method. We used the c2 test to compare proportions
between two groups. A p value <0.05 was considered
significant.3. Results
The overall prevalence of HAV was 96.7% among
the inhabitants of northeastern China, 99.7% (95% CI:
99.0e100.3) among the population of indigenous
Chinese, and 93.7% (95% CI: 90.9e96.4) among
Koreans living in China. In the former, the prevalence of
HAV was 99.2% (124/125) in men and 100.0% (175/
175) in women with no significant difference between
the two. In terms of age, the ratios were 99.4% (among
individuals in their 40s), 100.0% (50s), and 100.0%
(over 60 years of age) with no significant differences
between age groups. Among Koreans living in China,
the prevalence was 94.6% (123/130) in men and 92.9%
(158/170) in women with no significant difference
between the two; in terms of age, the ratios were 93.1%
(among individuals in their 40s), 91.3% (50s), and 100%
(over 60 years of age) with no significant differences
between age groups.
The overall prevalence of HAV was 98.0% (95% CI:
96.4e99.6) among the inhabitants of South Korea:
98.2% (111/113) in men and 97.9% (183/187) in
women. The age ratios were 95.8% (among individuals
in their 40s), 99.1% (50s), and 100.0% (over 60 years
of age).
The overall prevalence of HAV was 26.9% among
inhabitants of Japan: 20.4% (95% CI: 15.8e25.0)
among indigenous Japanese and 33.3% (95% CI:
28.0e38.7) among Koreans living in Japan. Among
indigenous Japanese, the prevalence was 13.4% (17/
127) in men and 25.6% (44/172) in women with
a significant difference (p Z 0.010) between the two;
the age ratios were 4.7% (among individuals in their
40s), 20.0% (50s), and 55.0% (over 60 years of age)
with a significant and gradual increase noted with
increasing age (p < 0.00004). Among Koreans living in
Japan, the prevalence was 34.4% (44/128) in men and
32.6% (56/172) in women with no significant difference
between the two; the age ratios were 6.8% (among
individuals in their 40s), 40.7% (50s), and 78.3% (over
60 years of age) with a significant and gradual increase
noted with increasing age (p < 0.00004) (Figure. 1AeC)
(Table 1).
Figure 1. Prevalence of HAV. Prevalence among Koreans living in northeastern China, indigenous Chinese, indigenous Koreans,
Koreans living in Japan, and indigenous Japanese (A). Prevalence by sex (B) and age (C) among the five population groups. Men:
open bar; women: hatched bar. *pZ 0.010; ** p < 0.00004. Ages are indicated as follow: 0e49 years of age, hatched bar; 50e59
years, open bar; > 60 years, closed bar.
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Since 2001, Korea has experienced a nationwide
outbreak of HAV, as reported in the nationwide
surveillance report on acute HAV published by KCDC-
Korea. The number of annual reported cases of HAV in
2005 was 798, which increased to 2081 in 2006 and
2233 in 2007. The number of cases exhibited an abrupt
increase from 2008 (nZ 7,895) to 2009 (nZ 15, 231),
but appeared to be declining in 2010 (nZ 6,794 through
Oct 2010). As a result of improved standards of hygiene
and sanitation, HAV epidemiology has rapidly shifted in
Korea. At present, adolescents and young adult are the
most susceptible to HAV infection because they were
not naturally infected with HAV during childhood, nor
have they been immunized against HAV [13e18].
In the past, HAV was endemic in South Korea
(especially in the 1980s), and most adults acquired
natural immunity through asymptomatic infection
[13,14]. Due to improved socioeconomic and sanitation
conditions, the epidemiological pattern of HAV has
rapidly improved in Korea; the seroprevalence has
decreased in children, teenagers, and young adults in
their 20s, though there has been an abrupt increase in
patients aged 20e30 years [16,19,20]. The seropreva-
lence is now very low in teenagers or those in their 20s,
higher among people in their 30s, and >90% amongolder patients [18,19]. Patients with HAV are mostly in
their 20s (57.5%) and 30s (31.5%). The number of
patients in the age groups (20 or >40 years) is rela-
tively lower (5.2 and 5.7 %, respectively) [19].
In 2007, Lu et al reported the serological prevalence
of viral HAV, B, C, and E in 8762 randomly selected
Chinese subjects in six areas of China in a cross-
sectional study. The overall prevalence of the anti-HAV
antibody was as high as 72.87% [21]. Anti-HAV prev-
alence in the 5, 10, 20, 30, 40, 50, 60, and
> 60 years age groups was 44.7%, 51.9%, 57.6%,
73.5%, 88.3%, 91.1%, 93.5%, and 97.3%, respectively
[21]. In Heilongjiang, which is located in northeastern
China, the prevalence of anti-HAV was over 95% in the
population > 40 years of age. Yanbian is also located in
Northeastern China, and the seroprevalence in our study
is consistent with previously published studies on China
[21e25]. In this region there are significant differences
between the two ethnic groups (i.e., Koreans living in
China and indigenous Chinese). The rate of HAV
seroprevalence was also found to be over 95% in
Koreans > 40 years of age. These results suggest that
the northeast region of China and South Korea might be
highly endemic to HAV.
According to the current age-specific rates of
immunity to HAV in various regions around the world
that were obtained by conducting a systematic review
Table 1. Prevalence of HAV among indigenous Japanese, Koreans living in Japan, indigenous Chinese, Koreans living in
northeastern China, and indigenous Koreans
Japan (n Z 599)
Indigenous Japanese Koreans living in Japan
Age (y) 0e49 50e59 >60 Total 0e49 50e59 >60 Total
Men 2/55 6/48 9/24 17/127 5/55 20/48 19/25 44/128
% positive 3.6 12.5 37.5 13.4 9.1 41.7 76.0 34.4
Women 4/74 16/62 24/36 44/172 4/77 24/60 28/35 56/172
% positive 5.4 25.8 66.7 25.6 5.2 40.0 80.0 32.6
Total 6/126 22/110 33/60 61/299 9/132 44/108 47/60 100/300
% positive
(95% CI)
4.7 20.0 55.0 20.4 (15.8e25.0) 6.8 40.7 78.3 33.3 (28.0e38.7)
China (n Z 600)
Indigenous Chinese Koreans living in northeastern China
Age (y) 0e49 50e59 >60 Total 0e49 50e59 >60 Total
Men 68/69 33/33 23/23 124/125 40/41 51/57 32/32 123/130
% positive 98.6 100.0 100.0 99.2 97.6 89.5 100.0 94.6
Women 90/90 57/57 28/28 175/175 55/61 65/70 38/38 158/170
% positive 100.0 100.0 100.0 100.0 90.2 92.9 100.0 92.9
Total 158/159 90/90 51/51 299/300 95/102 116/127 70/70 281/300
% positive
(95% CI)
99.4 100.0 100.0 99.7 (99.0e100.0) 93.1 91.3 100.0 93.7 (90.9e96.4)
South Korea (n Z 300)
Indigenous Koreans
Age (y) 0e49 50e59 >60 Total
Men 43/45 37/37 31/31 111/113
% positive 95.6 100.0 100.0 98.2
Women 71/74 69/70 43/43 183/187
% positive 95.9 98.6 100.0 97.9
Total 114/119 106/107 74/74 294/300
% positive
(95% CI)
95.8 99.1 100.0 98.0 (96.4e99.6)
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Korea, and Singapore the estimated level of endemicity
“very low,” which means <50% of the populations has
immunity by age 30 [3]. A study of the shifting seroe-
pidemiological patterns of HAV found an association
with improved sanitary conditions in Japan. The overall
seroprevalence was 12.2% in 2,430 serum specimens
obtained during 2003. Anti-HAV antibodies are rarely
detected in individuals between 0e44 years of age,
although the prevalence in individuals >50 years was
50.3% in 2003 [26]. These results were significantly
lower than those of corresponding studies conducted in
1994 (74.3%), 1984 (96.9%) and 1973 (96.9%) [26,27].
In our study, the samples obtained from a total of 1,500
men and women aged >40 years were collected from
May 2005 through February 2008. The overall prevalence
of HAV was 26.9% among the inhabitants of Japan:
20.4% (95% CI: 15.8e25.0) of indigenous Japanese and
33.3% (95% CI: 28.0e38.7) of Koreans living in Japan.
The decline in the prevalence of anti-HAV is consistent
with previous studies conducted in Japan [26,27].
Although further efforts are needed to clarify the
prevalence of HAV in younger generations (i.e., those
younger than 30 years of age) and the mode oftransmission mode, this study does provide certain
important information concerning the prevalence of
HAV in northeastern China, South Korea, and Japan
based on socioeconomic status, environmental condi-
tions, and ethnicity. Our data show that among people
> 40 years of age, the prevalence of anti-HAV is not
significantly different between northeastern China and
South Korea; however, this prevalence is different in
Japan. These results suggest that differences in sero-
prevalence could be attributed to geological, environ-
mental, and socioeconomic changes rather than
ethnicity.Acknowledgements
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